Drugs /

phenelzine

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for phenelzine

Phenelzine has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating phenelzine, 1 is phase 1 (0 open) and 1 is phase 2 (1 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for phenelzine clinical trials.

Breast carcinoma and prostate adenocarcinoma are the most common diseases being investigated in phenelzine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Phenelzine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Phenelzine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating phenelzine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
phenelzine (substance), hydrazine, (2-phenylethyl)-, β-phenylethylhydrazine, phenelzine, 2 phenethylhydrazine, beta-phenylethylhydrazine, 2-phenethylhydrazine, phénelzine, phenelzinum, maoi - phenelzine, fenelzin, phenelzine, fenelzina, phenelzine (product), phenelzin, phenelzine [chemical/ingredient], beta phenylethylhydrazine, phenethylhydrazine
NCIT ID [1]:
C61888
SNOMED ID [1]:
C-62420

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.